Bupropion Treatment for Youth Smoking Cessation

Last updated: June 23, 2006
Sponsor: University of Arizona
Overall Status: Completed

Phase

3

Condition

Stimulant Use Disorder

Tobacco Use Disorder

Treatment

N/A

Clinical Study ID

NCT00344695
3R01CA077081-04S1
  • Ages 14-17
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 14 to 17 years of age

  • Smoked at least 6 cigarettes per day

  • Exhaled CO greater than or equal to 10 ppm

  • Made at least two previous quit attempts

  • Weighed at least 90 pounds

  • Able to read English at least the 6th grade level

  • Motivated to quit smoking as evidenced by willingness to commit to study protocolrequirements for the duration of the study

  • provided active parental consent and youth assent

Exclusion

Exclusion Criteria:

  • Current use of tobacco products other than cigarettes, unless willing to abstain fromthese products for the study duration

  • Current use of other treatments for smoking cessation

  • History or current diagnosis of panic disorder, psychosis, bipolar disorder, or eatingdisorder

  • History of abuse or dependence on alcohol or other recreational or prescription drugsin the three months preceding the study

  • Current evidence of clinical depression or Attention Deficit/Hyperactivity Disorder

  • Use of any psychoactive drug and/or any type of antidepressant with in four weeks ofthe treatment phase of the study

  • Predisposition to seizure or tic disorders or a personal history of a seizuredisorder, family history of seizure disorders, or treatment with medication ortherapies that increase the risk of seizures

  • Significant history of or current clinical evidence of cardiovascular disease

  • (Females)Pregnancy (urine pregnancy test), lactation or, if sexually active,unwillingness to use a medically acceptable form of contraception for the duration ofthe study

  • Only one member of a household was allowed to participate in the study concurrently.

Study Design

Study Start date:
Estimated Completion Date:
April 30, 2003

Connect with a study center

  • University of Arizona

    Tucson, Arizona 85724
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.